FibroGen, Inc.
FGEN
$6.89
-$0.03-0.43%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 185.64% | 168.09% | -68.69% | -67.59% | -68.98% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 185.64% | 168.09% | -68.69% | -67.59% | -68.98% |
| Cost of Revenue | -72.09% | -57.59% | -40.62% | -30.85% | -3.42% |
| Gross Profit | 110.93% | 100.13% | 9.34% | 3.83% | -41.71% |
| SG&A Expenses | -18.34% | -24.97% | -63.41% | -59.02% | -52.64% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -61.31% | -50.20% | -48.05% | -39.93% | -20.07% |
| Operating Income | 90.20% | 80.71% | 36.67% | 28.78% | 2.00% |
| Income Before Tax | 80.28% | 71.98% | 39.80% | 30.62% | 3.65% |
| Income Tax Expenses | 22.88% | 4.37% | -1,448.39% | -667.21% | -200.00% |
| Earnings from Continuing Operations | 80.34% | 72.03% | 39.95% | 30.74% | 3.86% |
| Earnings from Discontinued Operations | 198.22% | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 95.84% | 83.26% | 58.60% | 47.76% | 21.71% |
| EBIT | 90.20% | 80.71% | 36.67% | 28.78% | 2.00% |
| EBITDA | 90.68% | 80.95% | 35.71% | 28.14% | 1.02% |
| EPS Basic | 95.85% | 83.58% | 59.90% | 49.71% | 25.17% |
| Normalized Basic EPS | 87.71% | 79.22% | 36.42% | 29.27% | 3.88% |
| EPS Diluted | 95.85% | 83.58% | 59.90% | 49.71% | 25.17% |
| Normalized Diluted EPS | 87.71% | 79.22% | 36.42% | 29.27% | 3.88% |
| Average Basic Shares Outstanding | 2.52% | 3.14% | 3.10% | 3.72% | 4.33% |
| Average Diluted Shares Outstanding | 2.52% | 3.14% | 3.10% | 3.72% | 4.33% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |